|Videos|September 22, 2017

What Makes ABSSSI Antibiotic Iclaprim Unique?

Author(s)Contagion&reg Editorial Staff

William D. O’Riordan, MD, FACEP, explains what makes iclaprim a unique antibiotic.

William D. O’Riordan, MD, FACEP, chief medical officer, eStudySite, explains how iclaprim has a unique mechanism of action, making it a unique antibiotic to treat acute bacterial skin and skin structure infections. Dr. O’Riordan explains how dihydrofolate reductase interferes with an enzyme that is involved with the bacterial cell and essentially “does away” with it.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Latest CME

Virtual Event

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

What Makes ABSSSI Antibiotic Iclaprim Unique?

Related Content

Wastewater Surveillance’s Role in Identifying Measles Outbreaks

Comparable Safety and No Emergent Resistance With Ceftobiprole vs Daptomycin in S aureus Bacteremia

Post-Exposure Protocol for STDs Prompts Resistant Gonorrhea

Ciprofloxacin, Levofloxacin, and Moxifloxacin: A Clinical Comparison of Fluoroquinolone Safety and Use

Nitrofurantoin Superior to Fosfomycin for Uncomplicated UTI

Latest CME

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Iowa Oncology Society

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation

Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Wyoming State Oncology Society

Tennessee Oncology Practice Society

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Kansas Society of Clinical Oncology

North Carolina Oncology Association

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Breaking the Demodex Blepharitis Cycle: The Importance of Early Intervention

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Community Practice Connections™: 18th Annual New York GU Cancer Congress™

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

SimulatEd™ in Hypercortisolism and Type 2 Diabetes: Identifying Patients with Hypercortisolism

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Southern California Psychiatry Conference

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

25th Annual International Congress on the Future of Breast Cancer® East

Retina Updates in Montréal

25th Annual International Congress on the Future of Breast Cancer® West